VTYX News and Press, Ventyx Biosciences Inc. From 10/10/23

2023-10-10 13:10:42 ET More on 5E Advanced Materials 5E Advanced Materials, Inc. (FEAM) Q4 2023 Earnings Call Transcript 5E Advanced Materials hires new contractors to complete small scale boron facility Seeking Alpha’s Quant Rating on 5E Advanced Materials ...

2023-10-10 12:55:00 ET Shares of Ventyx Biosciences (NASDAQ: VTYX) were down more than 26% as of noon on Tuesday after investors were unimpressed by the healthcare company's phase 2 trial results for ulcerative colitis (UC) therapy VTX002. The stock is down more than 31% so far ...

2023-10-10 10:00:01 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further deta...

2023-10-10 05:05:27 ET Related stories Hyatt Hotels: Expect Room Bookings And Pricing To Continue Growing PagerDuty: Now On Consumption-Based Pricing, At 38x EPS? Not For Me PagerDuty, Inc. 2024 Q2 - Results - Earnings Call Presentation For further details se...

2023-10-09 17:01:06 ET More on Ventyx Biosciences Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Ventyx Biosciences Historical earni...

VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and tolerability profile Ventyx to host conference call and webcast today at 4:30 PM ET SA...

2023-08-14 00:03:54 ET Summary Ventyx Biosciences is developing small-molecule therapies for inflammatory diseases with unmet needs. The company's primary candidate, VTX958, showed promising Phase 1 results and is currently in Phase 2 trials for various diseases. Ventyx has a ...

2023-08-13 11:11:02 ET Start Time: 16:30 End Time: 17:23 Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Raju Mohan - Founder and CEO Marty Auster - CFO Bill Sandborn - President and Chief...

2023-08-10 16:50:27 ET Ventyx Biosciences press release ( NASDAQ: VTYX ): Q2 GAAP EPS of -$0.91 misses by $0.20 . Cash, cash equivalents and marketable securities were $332.3 million as of June 30, 2023. For further details see: Ventyx Biosciences GAAP EPS of...

Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2023 Initiated a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, in adu...